DK4117667T3 - Sekventiel behandling af kræft ved hjælp af 6-thio-dg og checkpointhæmmere - Google Patents

Sekventiel behandling af kræft ved hjælp af 6-thio-dg og checkpointhæmmere Download PDF

Info

Publication number
DK4117667T3
DK4117667T3 DK21767125.4T DK21767125T DK4117667T3 DK 4117667 T3 DK4117667 T3 DK 4117667T3 DK 21767125 T DK21767125 T DK 21767125T DK 4117667 T3 DK4117667 T3 DK 4117667T3
Authority
DK
Denmark
Prior art keywords
thio
cancer
checkpoint inhibitors
sequential treatment
sequential
Prior art date
Application number
DK21767125.4T
Other languages
Danish (da)
English (en)
Inventor
Jerry Shay
Yang-Xin Fu
Ilgen Mender
Anli Zhang
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of DK4117667T3 publication Critical patent/DK4117667T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
DK21767125.4T 2020-03-13 2021-03-12 Sekventiel behandling af kræft ved hjælp af 6-thio-dg og checkpointhæmmere DK4117667T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062989041P 2020-03-13 2020-03-13
PCT/US2021/022090 WO2021183873A1 (en) 2020-03-13 2021-03-12 Sequential treatment of cancers using 6-thio-dg, checkpoint inhibitors and radiation therapy

Publications (1)

Publication Number Publication Date
DK4117667T3 true DK4117667T3 (da) 2025-02-10

Family

ID=77671975

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21767125.4T DK4117667T3 (da) 2020-03-13 2021-03-12 Sekventiel behandling af kræft ved hjælp af 6-thio-dg og checkpointhæmmere

Country Status (16)

Country Link
US (2) US12097213B2 (enExample)
EP (1) EP4117667B1 (enExample)
JP (1) JP7829491B2 (enExample)
KR (1) KR20220154134A (enExample)
CN (1) CN115397428A (enExample)
BR (1) BR112022018238A2 (enExample)
CA (1) CA3170930A1 (enExample)
DK (1) DK4117667T3 (enExample)
ES (1) ES3014683T3 (enExample)
FI (1) FI4117667T3 (enExample)
HU (1) HUE070513T2 (enExample)
IL (1) IL296403A (enExample)
MX (1) MX2022011331A (enExample)
PL (1) PL4117667T3 (enExample)
PT (1) PT4117667T (enExample)
WO (1) WO2021183873A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210023107A1 (en) 2018-03-22 2021-01-28 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
WO2025090539A1 (en) * 2023-10-22 2025-05-01 Regeneron Pharmaceuticals, Inc. Treatment of non-small cell lung cancer with 6-thio-dg and cemiplimab

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2630255B1 (en) * 2010-10-22 2014-09-10 Roche Diagnostics GmbH A conjugate between a thiophilic solid phase and an oligonucleotide comprising a thiooxonucleotide
NZ713498A (en) 2013-04-08 2017-07-28 Univ Texas Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US20180036331A1 (en) 2016-03-24 2018-02-08 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
WO2017205756A1 (en) 2016-05-27 2017-11-30 The Board Of Regents Of The University Of Texas System 6-thio-2'-deoxyguanosine (6-thio-dg) results in telomerase dependent telomere dysfunction and cell death in therapy-resistant cancer cells
WO2018049474A1 (en) 2016-09-16 2018-03-22 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
MA47604A (fr) 2017-02-21 2020-01-01 Regeneron Pharma Anticorps anti-pd-1 pour le traitement du cancer du poumon
US11571459B2 (en) 2017-04-03 2023-02-07 Oncxerna Therapeutics, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
EP3746119A4 (en) * 2018-02-01 2021-11-10 Merck Sharp & Dohme Corp. METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY
US20210113602A1 (en) 2018-02-28 2021-04-22 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-2'-DEOXYGUANOSINE (6-THIO-dG) TO TREAT MELANOMA
US20210023107A1 (en) 2018-03-22 2021-01-28 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS

Also Published As

Publication number Publication date
WO2021183873A1 (en) 2021-09-16
PL4117667T3 (pl) 2025-04-07
IL296403A (en) 2022-11-01
US12097213B2 (en) 2024-09-24
US20210290652A1 (en) 2021-09-23
EP4117667A4 (en) 2023-11-15
CA3170930A1 (en) 2021-09-16
JP2023517671A (ja) 2023-04-26
FI4117667T3 (fi) 2025-02-10
JP7829491B2 (ja) 2026-03-13
EP4117667A1 (en) 2023-01-18
AU2021233023B2 (en) 2026-04-16
PT4117667T (pt) 2025-02-06
ES3014683T3 (en) 2025-04-24
EP4117667B1 (en) 2024-12-18
AU2021233023A1 (en) 2022-11-03
HUE070513T2 (hu) 2025-06-28
MX2022011331A (es) 2022-10-27
BR112022018238A2 (pt) 2022-10-25
CN115397428A (zh) 2022-11-25
KR20220154134A (ko) 2022-11-21
US20240424013A1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
DK3860990T3 (da) Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer
DK4181920T3 (da) Kat6-inhibitor og kombinationer til behandling af brystkræft
DK3818086T3 (da) Behandling og forebyggelse af cancer under anvendelse af HER3-antigenbindende molekyler
DK4161935T3 (da) Brm-målrettende forbindelser og tilhørende anvendelsesmetoder
IL288061A (en) Compounds and methods for the treatment of covid-19
DK3966206T3 (da) Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf
DK3902803T3 (da) Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft
IL309086A (en) Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
IL287768A (en) Kcnt1 inhibitors and methods of use
IL287751A (en) Kcnt1 inhibitors and methods of use
DK3752251T3 (da) Arginasehæmmere og fremgangsmåder til anvendelse deraf
DK4497438T3 (da) Tricykliske parp1-hæmmere og deres anvendelse
DK4125842T3 (da) Samtidig indgivelse af mirdametinib og lifirafenib til anvendelse til behandling af kræftformer
DK3325623T3 (da) Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
DK3755816T3 (da) Fremgangsmåder til påvisning og behandling af prostatacancer
DK3601296T3 (da) 2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere
IL299700A (en) Kcnt1 inhibitors and methods of use
DK4200018T3 (da) Anti-par-2-antistoffer og fremgangsmåder til anvendelse deraf
DK4117667T3 (da) Sekventiel behandling af kræft ved hjælp af 6-thio-dg og checkpointhæmmere
IL286485A (en) Pi4-kinase inhibitors and methods of using the same
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer
DK3840837T3 (da) Arginasehæmmere og fremgangsmåder til anvendelse deraf
DK3402532T3 (da) Hæmning af ataxia telangiectasia og rad3-relateret protein (atr)